Unresponsive to Treatment

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

1 week ago talkbio0Tagged Adverse event, Clinical Trials, Diffuse Large B-Cell Lymphoma, Merck, middle dose, Relapsing course, ROR1 protein, human, Safety, therapeutic autologous dendritic cells, Unresponsive to Treatment, vedotin, waveLINE-003, Zilovertamab

Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025

FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

7 months ago talkbio0Tagged Acute leukemia, Approved, Chromosomal translocation, KMT2A gene, Menin Inhibitor, Relapsing course, Revuforj, Syndax, United States Food and Drug Administration, Unresponsive to Treatment

FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals

FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma

12 months ago talkbio0Tagged Antibodies, Bispecific, Approved, Engaged to be married, epcoritamab-bysp, EPKINLY, Lymphoma, Follicular, Relapsing course, Subcutaneous Treatment, T-Lymphocyte, United States Food and Drug Administration, Unresponsive to Treatment

EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment